Over 16 years of living with ALS, Dagmar Munn says she has changed the way she responds when her body does not move the way she expects: https://bit.ly/4e39UN4
@alsnewstoday.bsky.social
@alsnewstoday.bsky.socialOver 16 years of living with ALS, Dagmar Munn says she has changed the way she responds when her body does not move the way she expects: https://bit.ly/4e39UN4
@alsnewstoday.bsky.socialExplore the details: https://bit.ly/4hAsKMH
A progressive decline in lung function is unavoidable in ALS, but there are steps that patients can take to improve breathing issues.
@alsnewstoday.bsky.socialDiscover more: https://bit.ly/3TT7da2
Low muscle mass in the arms and legs and sarcopenia were linked to poorer survival in people with ALS in a small prospective study.
@alsnewstoday.bsky.socialA targeted treatment for a rare genetic form of ALS has met its main goal in a Phase 3 trial.
Read more: https://bit.ly/3TpqLCD
@alsnewstoday.bsky.socialTake a closer look: https://bit.ly/46Ie6Os
Columnist Kristin Neva takes note of the changing seasons with an initial sense of dread, then refocuses on the good things that also come.
@alsnewstoday.bsky.socialDiscover more: https://bit.ly/4d3W4tt
Phase 3 FUSION results suggest a targeted therapy may slow disease progression in FUS-ALS, with benefits seen versus placebo.
@alsnewstoday.bsky.social“While scrolling through social media the other day, I came across a question that stopped me in my tracks: How has having ALS impacted your life for the better?” -Dagmar Munn
Continue with this reading: https://bit.ly/47evVoo
@alsnewstoday.bsky.socialGet the scoop: https://bit.ly/4xNkXRH
ALS disrupted her relationship with her body, so columnist Dagmar Munn developed small, intentional habits to restore her confidence.
@alsnewstoday.bsky.socialTake a closer look: https://bit.ly/3VMK4qj
Mouse model study finds molecular changes in inflammation, RNA, and protein processing before ALS symptoms appear.
@alsnewstoday.bsky.socialExplore the details: https://bit.ly/4cXwy9l
ALS may change what marriage looks like for guest columnist Nancy Muirhead and her husband, but it cannot change their love.
@alsnewstoday.bsky.socialTake a closer look: https://bit.ly/4Aokzvz
Researchers identified changes in 10 genes that may help diagnose or track ALS, according to a computer analysis of thousands of genes.
@alsnewstoday.bsky.socialA woman with a progressive motor neuron disease was able to generate her own words in real time using an investigational brain-computer interface: https://bit.ly/475unNs
#ALS #ALSResearch #BrainComputerInterface #ALSNewsToday #Bionews
@alsnewstoday.bsky.socialTake a closer look: https://bit.ly/4ApNKyi
The first healthy participant has been dosed in a Phase 1 clinical trial of ACE-2223, an experimental treatment for ALS.
@alsnewstoday.bsky.socialTake a closer look: https://bit.ly/4y2rith
Geneuro received a European patent for GNK-301, an ALS therapy candidate targeting a viral protein thought to contribute to the disease.
@alsnewstoday.bsky.socialDiscover more: https://bit.ly/46xm50F
A brain-computer interface enabled a woman with a motor neuron disease to generate her own words in real time, according to its developer.
@alsnewstoday.bsky.socialDiscover more: https://bit.ly/4jaBz20
Columnist Kristin Neva pauses to reflect on the uncertainty of living with ALS, even as she commits to making memories with her husband.
@alsnewstoday.bsky.socialTake a closer look: https://bit.ly/3TCmdcf
Keynote speaker Mindy Henderson redefines "impossible" ahead of MDA Engage: Chicago, taking place Sept. 25-26 at the Westin Chicago Lombard.
@alsnewstoday.bsky.socialWhen “How are you feeling?” is always a complicated question as a patient or caregiver. 😅
Living with ALS or caring for someone who is? Connect with others who get it: https://bit.ly/4rcO8vI
@alsnewstoday.bsky.socialGet the scoop: https://bit.ly/4AiSiX1
A fitness routine columnist Dagmar Munn developed for a wellness project became a core part of her own exercise regimen after her diagnosis.
@alsnewstoday.bsky.socialTake a closer look: https://bit.ly/4heYC9u
The 100th participant has been enrolled in a Phase 2/3 clinical trial testing COYA 302, Coya Therapeutics’ experimental therapy for ALS.